About Us

HCW Biologics (“HCWB” or the “Company”) is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This
field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions,
including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.

The Company has active programs based on three lead molecules that were created with a proprietary Tissue FactOr-Based FusIon (TOBI™) platform, or TOBI platform. The TOBI platform is designed to engineer multi-functional fusion protein molecules and protein complexes. It employs a Tissue Factor (TF) scaffold that can be packaged with multiple protein targets, including cytokines, chemokines, ligands, receptors, and single-chain antibodies.